A randomized phase II trial of gemcitabine, nab‐paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer

The MSKD is feasible in patients with PDAC and, although not powered for definitive outcomes, shows trends in improved PFS and OS when combined with gemcitabine, nab-paclitaxel, and cisplatin, without added toxicity or detriment to QOL. Larger studies are required to confirm these findings and establish the value of the MSKD in pancreatic cancer treatment.

Authors

Institutions

Publication Details

Journal
Cancer
Published
2026-03-12
DOI
https://doi.org/10.1002/cncr.70343
Primary Topic
Diet and metabolism studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A randomized phase II trial of gemcitabine, nab‐paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer

Gayle Jameson, Denise J. Roe, Richard C. Frank, Angela Alistar et al.
Cancer
Diet and metabolism studies
article

A randomized phase II trial of gemcitabine, nab‐paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer

Gayle Jameson, Denise J. Roe, Richard C. Frank, Angela Alistar, Stephen Gately, Caroline G. P. Roberts, Derek Cridebring, Jennifer Keppler, Alan M. Miller, Erkut Borazanci, Sarah J. Hallberg, Drew Rasco, Sunil Sharma, Keehoon Lee, Diana L. Hanna, J. Erin Wiedmeier‐Nutor, Joshua D. Rabinowitz, Daniel D. Von Hoff, Sandra D. Algaze, Betsy C. Wertheim, Meredith S. Pelster, Alison R. Zoller
article en

Abstract

The MSKD is feasible in patients with PDAC and, although not powered for definitive outcomes, shows trends in improved PFS and OS when combined with gemcitabine, nab-paclitaxel, and cisplatin, without added toxicity or detriment to QOL. Larger studies are required to confirm these findings and establish the value of the MSKD in pancreatic cancer treatment.

CancerVol. 132(6)
Norwalk Hospital (US), Translational Genomics Research Institute (US), City Of Hope National Medical Center (US), University of Arizona (US), Princeton University (US), WinnMed (US), Morristown Medical Center (US), Denver Public Health (US), Sarah Cannon (US), City of Hope (US), USC Norris Comprehensive Cancer Center (US), South Texas Accelerated Research Therapeutics (US), HonorHealth (US), Pinnacle Oncology Hematology (US), Mayo Clinic in Florida (US), Arizona Oncology (US), University of Arizona Cancer Center, Arizona State University (US), Atlantic Health System (US)
Good health and well-being
Openalex Percentile: Top 25%
Diet and metabolism studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.